샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785837

세계의 비구아니드 시장

Biguanides
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 268 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 비구아니드 시장은 2030년까지 59억 달러에 도달

2024년에 51억 달러로 추정된 비구아니드 세계 시장은 2024-2030년의 분석 기간에 CAGR 2.5%로 성장하여 2030년에는 59억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Metformin은 CAGR 3.1%를 나타내고, 분석 기간 종료시에는 35억 달러에 이를 것으로 예측됩니다. Phenformin 부문의 성장률은 분석 기간중 CAGR 1.7%로 추정됩니다.

미국 시장은 14억 달러로 추정, 중국은 CAGR 5.0%로 성장 예측

미국의 비구아니드 시장은 2024년에 14억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 11억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 0.9%와 1.9%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.4%를 보일 전망입니다.

세계의 비구아니드 시장 - 주요 동향과 촉진요인 정리

비구아니드가 당뇨병과 항균제 치료에 중요한 요소인 이유는 무엇인가?

비구아니드는 주로 2형 당뇨병 치료에 사용되는 약물의 일종으로 혈당을 낮추고 인슐린 감수성을 개선하는 효과가 있어 당뇨병 관리의 핵심으로 자리 잡고 있습니다. 가장 널리 처방되는 비구아나이드 계열의 약물인 메트포르민은 말초에서 포도당 흡수를 촉진하고 간에서 포도당 생성을 감소시키는 역할을 하는 것으로 세계적으로 인정받고 있습니다. 전 세계적으로 2형 당뇨병 및 대사 이상 유병률이 증가함에 따라 의료진은 비용 효율적이고 신뢰할 수 있는 치료법을 찾고 있으며, 이에 따라 비구아나이드에 대한 수요는 지속적으로 증가하고 있습니다. 또한, 비구아니드는 당뇨병 치료 외에도 노화 방지, 암 치료, 심혈관 질환 예방 등에도 적용 가능성을 시사하는 새로운 연구 결과도 있어 유망한 것으로 평가받고 있습니다.

비구아니드는 대사 건강의 역할을 넘어 항균 특성, 특히 소독제 및 방부제에도 널리 사용되고 있습니다. 비구아나이드계 화합물인 클로르헥시딘은 의료용 방부제, 구강위생용품, 수술용 소독제의 주요 성분입니다. 박테리아, 곰팡이, 바이러스에 대한 광범위한 항균 활성으로 병원 내 감염 방지 및 개인 위생 관리에 필수적인 제품입니다. 항생제 내성에 대한 우려가 커짐에 따라, 비구아니드와 같은 대체 항균 솔루션에 대한 수요는 제약, 헬스케어, 소비자 위생 시장 전반에서 증가하고 있습니다. 비구아니드는 현재 진행 중인 임상 연구를 통해 새로운 치료 용도를 모색하고 있으며, 대사성 질환 관리와 감염 예방에 있어 중요한 요소로 자리매김하고 있습니다.

기술의 발전은 어떻게 비구아니드 기반 치료를 강화시키고 있는가?

제형 및 약물 전달 시스템의 기술 혁신은 비구아니드 계열 치료제의 효능, 생체이용률, 안전성 프로파일을 크게 향상시키고 있습니다. 이 분야에서 가장 주목할 만한 발전 중 하나는 서방형(ER) 메트포르민 제제의 개발로, 위장관계 부작용을 줄이고 하루에 여러 번 복용해야 할 필요성을 최소화하여 환자의 복약 순응도를 높인 것입니다. 이러한 제제는 약물의 흡수를 증가시키고 보다 안정적인 혈당 조절을 제공하므로 장기적인 당뇨병 관리를 위해 선호되는 선택이 되고 있습니다. 또한, 나트륨-포도당 공수송체-2(SGLT2) 억제제와 디펩티딜 펩티데이즈-4(DPP-4) 억제제와 비구아니드를 병용하는 병용요법에 대한 연구가 진행되면서 복잡한 대사질환 환자들의 치료 성적이 개선되고 있습니다.

또 다른 큰 진전은 암이나 신경 퇴행성 질환과 같은 새로운 치료 영역에서 빅구아나이드를 탐구하는 것입니다. 최근 연구에 따르면, 메트포르민은 세포의 에너지 대사를 억제하고 종양의 증식을 억제하여 항암 작용을 하는 것으로 알려져 있습니다. 또한, 전임상 연구에 따르면 메트포르민은 신경 보호 효과가 있어 알츠하이머병 및 기타 신경 퇴행성 질환의 진행을 늦추는 역할을 할 수 있는 것으로 나타났습니다. 항균제 분야에서는 나노입자 기반 전달 시스템의 발전으로 병원 내 감염 예방과 상처 치유 개선에 있어 클로르헥시딘의 효능이 증가하고 있습니다. 제약회사와 바이오테크 기업이 연구개발에 대한 투자를 지속하는 가운데, 비구아니드 계열 치료제는 새로운 의료용도로 확대되어 현대 의학에서 관련성이 강화될 것으로 예측됩니다.

비구아나이드 시장의 성장을 견인하는 업계 동향은?

세계 비구아나이드 시장은 당뇨병 유병률 증가, 항균 솔루션에 대한 수요 증가, 신흥 치료 분야에서의 적용 확대 등으로 꾸준히 성장하고 있습니다. 시장을 형성하는 가장 영향력 있는 트렌드 중 하나는 2형 당뇨병 환자의 급증이며, 특히 신흥 경제국에서는 생활습관의 변화와 도시화로 인해 대사 이상 발생률이 높아지고 있습니다. 정부와 의료 기관이 당뇨병 관리의 우선순위를 정하고 있는 가운데, 메트포르민은 저렴한 가격과 입증된 효과로 인해 여전히 제1선택 약물로 자리매김하고 있습니다. 또한, 예방적 건강관리의 중요성이 강조되면서 검진 및 조기 진단이 증가하면서 비구아니드계 치료제에 대한 수요가 더욱 증가하고 있습니다.

시장에 영향을 미치는 또 다른 주요 동향은 의료 및 소비자 위생 관리에서 감염 통제에 대한 관심이 높아지고 있다는 점입니다. 코로나19 사태로 인해 항균제 내성에 대한 인식이 높아지고 효과적인 소독제의 필요성이 높아지면서 병원, 치과 치료 및 개인 위생 용품에서 클로르헥시딘과 같은 비구아니드계 소독제의 사용이 증가하고 있습니다. 또한, 원격 의료와 전자 약국의 확대로 인해 비구아니드 계열 약물에 대한 접근성이 개선되어 시장의 지속적인 성장을 보장하고 있습니다. 연구자들이 유전자 및 대사 프로파일을 기반으로 치료를 최적화하는 표적 치료법을 개발함에 따라 개인 맞춤형 의료, 특히 정밀 당뇨병 치료에서 비구아나이드에 대한 관심도 높아지고 있습니다. 혁신적이고 비용 효율적인 헬스케어 솔루션에 대한 수요가 지속적으로 증가함에 따라, 비구아나이드 시장은 다양한 치료 및 예방 용도로 확대될 것으로 예측됩니다.

비구아나이드 시장의 미래를 좌우할 주요 성장 촉진요인은 무엇인가?

비구아나이드 시장의 성장은 당뇨병 유병률 증가, 약물 연구에 대한 투자 증가, 비당뇨병 치료 영역에서의 용도 확대 등 여러 가지 요인에 의해 이루어지고 있습니다. 주요 성장 요인 중 하나는 현재 진행 중인 세계 당뇨병 유행으로, 2023년에는 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있는 것으로 추정됩니다. 메트포르민은 저렴한 가격과 수년간의 임상적 성공으로 인해 특히 첨단 치료법에 대한 접근성이 제한적인 신흥 시장에서 당뇨병 관리 전략의 핵심 요소로 자리매김하고 있습니다. 또한, 제약사들은 치료 효과를 높이고 부작용을 최소화하기 위해 새로운 약물 조합과 차세대 비구아니드 유사체를 모색하고 있습니다.

시장을 형성하는 또 다른 중요한 촉진요인은 항균 및 감염 제어 솔루션에 대한 요구가 증가하고 있다는 점입니다. 병원 내 감염(HAI)이 공중보건의 심각한 위험으로 떠오르면서 클로르헥시딘을 기반으로 한 방부제 및 소독제에 대한 수요는 지속적으로 증가하고 있습니다. 또한, 항균제 내성에 대한 인식이 높아지면서 약제 내성 병원균에 대한 효과를 높인 비구아나이드 유도체에 대한 연구가 진행되고 있습니다. 종양학, 신경보호, 장수연구에서 빅구아나이드의 잠재적 역할은 생명공학기업과 제약기업들의 관심을 불러일으키고 새로운 투자기회를 창출하고 있습니다. 과학의 발전으로 새로운 치료 용도가 속속 개발되고 규제 당국이 적응증 확대를 지지하는 가운데, 비구아나이드 시장은 지속적인 성장을 거듭하며 대사 및 항균 의료 분야에서 그 중요성을 확고히 하고 있습니다.

부문

유형(Metformin, Phenformin), 유통 채널(소매 약국 유통 채널, 병원 유통 채널, 기타 유통 채널)

조사 대상 기업 예

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AI 통합

검증된 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁합니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.14

Global Biguanides Market to Reach US$5.9 Billion by 2030

The global market for Biguanides estimated at US$5.1 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Metformin, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Phenformin segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.0% CAGR

The Biguanides market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Biguanides Market - Key Trends & Drivers Summarized

Why Are Biguanides a Critical Component in Diabetes and Antimicrobial Treatments?

Biguanides, a class of medications primarily used to treat type 2 diabetes, have remained a cornerstone of diabetes management due to their effectiveness in lowering blood glucose levels and improving insulin sensitivity. Metformin, the most widely prescribed biguanide, has gained global recognition for its role in reducing hepatic glucose production while enhancing peripheral glucose uptake. With the increasing prevalence of type 2 diabetes and metabolic disorders worldwide, the demand for biguanides continues to rise as healthcare providers seek cost-effective and reliable treatment options. Additionally, biguanides have shown promise beyond diabetes treatment, with emerging research suggesting potential applications in anti-aging, cancer therapy, and cardiovascular disease prevention.

Beyond their role in metabolic health, biguanides are also widely used for their antimicrobial properties, particularly in disinfectants and antiseptics. Chlorhexidine, a biguanide-based compound, is a key ingredient in medical-grade antiseptics, oral hygiene products, and surgical disinfectants. Its broad-spectrum antimicrobial activity against bacteria, fungi, and viruses has made it indispensable in hospital infection control and personal care applications. As concerns about antibiotic resistance grow, the demand for alternative antimicrobial solutions like biguanides is expanding across pharmaceutical, healthcare, and consumer hygiene markets. With ongoing clinical research exploring new therapeutic uses, biguanides are positioned to remain a vital component of both metabolic disease management and infection prevention.

How Are Technological Advancements Enhancing Biguanide-Based Treatments?

Innovations in pharmaceutical formulation and drug delivery systems are significantly improving the efficacy, bioavailability, and safety profile of biguanide-based treatments. One of the most notable advancements in this field is the development of extended-release (ER) metformin formulations, which offer better patient adherence by reducing gastrointestinal side effects and minimizing the need for multiple daily doses. These formulations enhance drug absorption and provide more stable glucose control, making them a preferred option for long-term diabetes management. Additionally, research into combination therapies that pair biguanides with sodium-glucose co-transporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is driving improved treatment outcomes for patients with complex metabolic conditions.

Another major breakthrough is the exploration of biguanides in new therapeutic areas, including oncology and neurodegenerative diseases. Recent studies have suggested that metformin possesses anti-cancer properties by inhibiting cellular energy metabolism and reducing tumor growth. Additionally, preclinical research indicates that biguanides may have neuroprotective effects, potentially playing a role in delaying the progression of Alzheimer’s disease and other neurodegenerative disorders. In the antimicrobial sector, advancements in nanoparticle-based delivery systems are enhancing the effectiveness of chlorhexidine in preventing hospital-acquired infections and improving wound healing. As pharmaceutical and biotech companies continue to invest in research and development, biguanide-based treatments are expected to expand into new medical applications, reinforcing their relevance in modern medicine.

Which Industry Trends Are Driving Growth in the Biguanides Market?

The global biguanides market is experiencing steady growth due to rising diabetes prevalence, increasing demand for antimicrobial solutions, and expanding applications in emerging therapeutic fields. One of the most influential trends shaping the market is the surge in type 2 diabetes cases, particularly in developing economies where lifestyle changes and urbanization have led to a higher incidence of metabolic disorders. With governments and healthcare organizations prioritizing diabetes management, metformin remains a first-line therapy due to its affordability and proven efficacy. Additionally, the growing emphasis on preventive healthcare has led to increased screening and early diagnosis, further driving demand for biguanide-based treatments.

Another key trend influencing the market is the rising focus on infection control in healthcare and consumer hygiene. The COVID-19 pandemic heightened awareness of antimicrobial resistance and the need for effective disinfectants, leading to increased use of biguanide-based antiseptics like chlorhexidine in hospitals, dental care, and personal hygiene products. Moreover, the expansion of telemedicine and e-pharmacies has improved access to biguanide medications, ensuring continued market growth. The exploration of biguanides in personalized medicine, particularly in precision diabetes care, is also gaining traction as researchers develop targeted therapies that optimize treatment based on genetic and metabolic profiles. As the demand for innovative and cost-effective healthcare solutions continues to rise, the biguanides market is expected to expand across multiple therapeutic and preventive applications.

What Are the Key Growth Drivers Shaping the Future of the Biguanides Market?

The growth in the biguanides market is driven by several factors, including increasing diabetes prevalence, rising investments in drug research, and expanding applications in non-diabetes therapeutic areas. One of the primary growth drivers is the ongoing global diabetes epidemic, with over 537 million adults estimated to have diabetes in 2023. The affordability and long-standing clinical success of metformin make it a critical component of diabetes management strategies, particularly in emerging markets with limited access to advanced therapies. Additionally, pharmaceutical companies are exploring novel drug combinations and next-generation biguanide analogs to enhance therapeutic efficacy and minimize side effects.

Another key driver shaping the market is the growing need for antimicrobial and infection control solutions. With hospital-acquired infections (HAIs) posing a significant public health risk, the demand for chlorhexidine-based antiseptics and disinfectants continues to rise. Furthermore, the increasing awareness of antimicrobial resistance has prompted research into biguanide derivatives with enhanced efficacy against drug-resistant pathogens. The potential role of biguanides in oncology, neuroprotection, and longevity research is also driving interest from biotech and pharmaceutical firms, leading to new investment opportunities. As scientific advancements continue to unlock new therapeutic applications and regulatory agencies support expanded indications, the biguanides market is poised for sustained growth, solidifying its importance in both metabolic and antimicrobial medicine.

SCOPE OF STUDY:

The report analyzes the Biguanides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Metformin, Phenformin); Distribution Channel (Retail Pharmacies Distribution Channel, Hospitals Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biguanides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Biguanides as a First-Line Therapeutic Class
    • Growing Demand for Cost-Effective Antidiabetic Drugs Drives Widespread Use of Metformin-Based Biguanides
    • Increased Focus on Metabolic Health and Pre-Diabetes Management Expands Addressable Market Opportunity for Biguanide Compounds
    • Scientific Advancements in Repurposing Biguanides for Cancer, Aging, and Cardiovascular Health Strengthen Long-Term Growth Prospects
    • Regulatory Endorsement of Metformin as a Gold-Standard Treatment Drives Continued Global Adoption
    • Emerging Research on Biguanides in Geroprotection and Longevity Science Spurs New Therapeutic Applications
    • Surge in Demand for Antimicrobial Agents Drives Biguanide Usage in Hospital-Grade Disinfectants and Antiseptics
    • Expansion of Personal Hygiene and Surface Disinfection Markets Strengthens the Business Case for Biguanide-Based Biocides
    • Growing Emphasis on Infection Control in Healthcare Facilities Fuels Demand for Biguanide Antiseptics Like Chlorhexidine
    • Interest in Combination Therapies and Drug Synergies Enhances Use of Biguanides in Multimodal Treatment Regimens
    • Rising Geriatric Population and Polypharmacy Trends Sustain Long-Term Demand for Well-Tolerated Biguanide Drugs
    • Low Cost and High Therapeutic Index of Biguanides Support Their Role in Essential Drug Lists and Public Health Programs
    • Emerging Interest in Biguanides for Weight Management and Insulin Sensitivity Strengthens Consumer and Clinical Demand
    • Increasing Pharmaceutical R&D Investments Drive Innovation in Modified-Release and Combination Formulations of Biguanides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biguanides Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Metformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phenformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제